Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Louis M. Staudt"'
Autor:
John Gerecitano, Jodi Carey, Christopher Major, Peter Johnson, Songbai Wang, Pier Luigi Zinzani, Wyndham H. Wilson, Steven Sun, Jessica Vermeulen, S. Martin Shreeve, Louis M. Staudt, Laurie H. Sehn, Michael Schaffer, Brendan P. Hodkinson, Sriram Balasubramanian
Publikováno v:
Br J Haematol
We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubic
Autor:
Louis M. Staudt, Amy S. Kimball, Sven de Vos, Jerry Ping, Darrin M. Beaupre, Wyndham H. Wilson, Da-Wei Huang, Kevin A. Kwei, George E. Wright, Leslie Popplewell, Jutta K. Neuenburg, Saurabh Chhabra, Tycel Phillips
Publikováno v:
Leukemialymphoma. 62(9)
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is difficult to cure; non-germinal center B-cell-like (non-GCB) and activated B-cell-like (ABC) DLBCL have worse outcomes than GCB DLBCL. Ibrutinib and lenalidomide are synergistic in vitro in
Autor:
Jeremy S. Abramson, Heiko Schöder, Wyndham H. Wilson, Richard I. Fisher, Nancy L. Bartlett, Matthew J. Maurer, Levi Pederson, John P. Leonard, Jane N. Winter, Nishitha Reddy, Louis M. Staudt, Nina D. Wagner-Johnston, Kristie A. Blum, Susan Mathew, Julie E. Chang, Ajay K. Gopal, Jonathan W. Friedberg, Brad S. Kahl, Amy Chadburn, Kristy L. Richards, Brandelyn N. Pitcher, Bruce D. Cheson, Mei Yin C. Polley, Andrew D. Zelenetz, Eric D. Hsi, Sin-Ho Jung
Publikováno v:
Journal of Clinical Oncology. 37:1790-1799
PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, v
Autor:
Sirpa Leppä, Su-Peng Yeh, Ronit Gurion, Mehmet Turgut, Sriram Balasubramanian, Laurie H. Sehn, Anas Younes, Sen Hong Zhuang, Xiaonan Hong, Pier Luigi Zinzani, Andres Lopez-Hernandez, Shinya Rai, Caterina Patti, S. Martin Shreeve, Wojciech Jurczak, David Belada, Matthew C. Cheung, Olga Samoilova, Cheolwon Suh, Jessica Vermeulen, Louis M. Staudt, Jodi Carey, Catherine Thieblemont, Peter Johnson, C.S. Chiattone, Ulrich Dührsen, Grace Liu, Wyndham H. Wilson, Steven Sun, Jun Zhu
Publikováno v:
Journal of Clinical Oncology. 37:1285-1295
60th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 01-04, 2018 -- San Diego, CA Jurczak, Wojciech/0000-0003-1879-8084; Johnson, Peter/0000-0003-2306-4974; ZINZANI, PIER LUIGI/0000-0002-2112-2651; Leppa, Sirpa/0000-0002-8265-511X W
Autor:
Hiyaa S. Ghosh, Louis M. Staudt, Catherine M. Sawai, Michele Ceribelli, Esther Z. Hou, Vanja Sisirak, Boris Reizis
Publikováno v:
Journal of Experimental Medicine
Journal of Experimental Medicine, Rockefeller University Press, 2020, 210, pp.2151-2159. ⟨10.1084/jem.20130443⟩
The Journal of Experimental Medicine
Journal of Experimental Medicine, Rockefeller University Press, 2020, 210, pp.2151-2159. ⟨10.1084/jem.20130443⟩
The Journal of Experimental Medicine
Exit of mature pDCs from the bone marrow requires the transcription factor Runx2, in part via Runx2-driven expression of CCR5.
Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to viruses and are essential
Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to viruses and are essential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221189fbb1dc23417c027ecfef761dda
https://hal.archives-ouvertes.fr/hal-03045713/document
https://hal.archives-ouvertes.fr/hal-03045713/document
Autor:
Wyndham H. Wilson, Milos D. Miljkovic, James D. Phelan, Anna Marie Juanitez, Amy Hillsman, Jagan R. Muppidi, Mark Roschewski, Amynah Pradhan, Michele Ceribelli, Seth M. Steinberg, Craig J. Thomas, Louis M. Staudt, Stefania Pittaluga, Rahul Lakhotia, Christopher Melani, Elaine S. Jaffe
Publikováno v:
Blood. 138:3537-3537
Background: Mantle cell lymphoma (MCL) is a biologically and clinically heterogenous B-cell lymphoma that is generally incurable with standard therapies. Novel targeted agents can disrupt key survival pathways in MCL such as regulation of apoptosis (
Autor:
Rahul Lakhotia, Jillian Simard, James D. Phelan, Jagan R. Muppidi, Elaine S. Jaffe, Lydia L. Chou, Louis M. Staudt, Stefania Pittaluga, Michail S. Lionakis, Andrea Nicole Lucas, Wyndham H. Wilson, Seth M. Steinberg, Matthias Holdhoff, Christopher Melani, Mark Roschewski, John A. Butman, Michael Glantz
Publikováno v:
Blood. 136:24-25
Background: Secondary CNS B-cell lymphomas (SCNSL) are aggressive lymphomas with a very poor prognosis. Genetic subtypes of DLBCL with CNS tropism are enriched for chronic active B-cell receptor signaling and may respond to BTK inhibition (BTKi). CLL
Autor:
Rahul Lakhotia, William D. Figg, Christopher Melani, Seth M. Steinberg, Elaine S. Jaffe, Wyndham H. Wilson, Sarah Evans, Jagan R. Muppidi, Louis M. Staudt, Stefania Pittaluga, Lydia L. Chou, Mark Roschewski, James D. Phelan
Publikováno v:
Blood. 136:39-40
Introduction Follicular lymphoma (FL) has a highly variable clinical course. Chemoimmunotherapy can induce durable remissions, but ~20% relapse early. The PI3K pathway is central to FL biology and multiple PI3K inhibitors (PI3Ki) are approved for FL,
Autor:
Wyndham H. Wilson, William D. Figg, Andrea Nicole Lucas, Rahul Lakhotia, Elaine S. Jaffe, Lydia L. Chou, Matthias Holdhoff, Catherine Lai, Christopher Melani, Cody J. Peer, Michail S. Lionakis, Jan Drappatz, S. Percy Ivy, Richard F. Little, John A. Butman, Louis M. Staudt, Stefania Pittaluga, Michael Glantz, James D. Phelan, Mark Roschewski, Seth M. Steinberg
Publikováno v:
Blood. 136:12-13
Background: Primary DLBCL of the CNS (PCNSL) relies on chronic active B-cell receptor (BCR) signaling. Ibrutinib targets BCR signaling through BTK inhibition (BTKi), which may also impair innate immunity. We showed that ibrutinib and temozolomide, et
Autor:
Christopher Melani, Elaine S. Jaffe, Seung Tae Lee, Rafic Farah, Milos D. Miljkovic, Wyndham H. Wilson, James D. Phelan, Anna Marie Juanitez, Rahul Lakhotia, Craig A. Portell, Craig J. Thomas, Mark Roschewski, Louis M. Staudt, Stefania Pittaluga, Jagan R. Muppidi, Michele Ceribelli, Seth M. Steinberg, Frances A. Tosto
Publikováno v:
Blood. 136:44-45
Background: Aggressive B-cell non-Hodgkin lymphoma (NHL) can be cured with chemoimmunotherapy; however, those who fail primary therapy and those with indolent NHL are rarely curable. Targeted agents can disrupt key survival pathways in NHL such as re